ID

Nowcasting consumer price inflation using high-frequency scanner data: evidence from Germany

Retrieved on: 
Tuesday, April 23, 2024
Consensus, Online, Cream, Honey, Tax, Glass, MAPI, Consensus Economics, Journal of Economic Perspectives, Milk, Shower, Low-alcohol beer, Autoregressive–moving-average model, Infant, C3, Islam, Wine, Core inflation, Research Papers in Economics, National accounts, Kálmán, Barcode, Journal of International Economics, Communication, Royal Statistical Society, COVID19, Kohl (cosmetics), Natural disaster, Business, Observation, Paper, VAT, European Economic Review, Diebold Nixdorf, Blancmange, Calendar, Sunflower oil, Annual Review of Economics, Hand, C4, DESTATIS, NBER, Tinning, Razor, Forecasting, Gasoline, Coffee, European Economic Association, Cat, Journal of Monetary Economics, Journal of Applied Econometrics, Medeiros, Architecture, Oxford University Press, Producer, GfK, Quarterly Journal of Economics, Margarine, NCBS, Starch, Political economy, Consistency, COVID-19, Consensus decision-making, Website, MIDAS, Behavior, Deutsche Bundesbank, PPI, World Bank, Collection, Medical classification, Orange, Eurozone, Butter, FMCG, Noise, Travel, Clothing, History, Inflation, Liver, International economics, Journal of Political Economy, BSI, OLS, Statistics, Consumer, PDF, University of Chicago, Classification, ECB, Fats, Policy, Multi, WOB, Outline, C6, Mincing, Canadian International Council, Social science, Perfume, University of California, Berkeley, Journal of Forecasting, Federal Reserve Bank, JEL, L1, Journal, Research, Candle, Food, TPD, Credit, Spice, LPG, Janssen, Marmalade, Superior, Literature, Chocolate, Beef, Kiel University, European Central Bank, Natural gas, HICP, Monetary economics, Yogurt, Section 5, ILO, Bermingham, Price, GTIN, Cheese, Macroeconomics, Growth, Beck, XJ, Government, De Beer, Supermarket, Ice cream, Naturally, C53, Corn flakes, BIS, Biscuit, LASSO, Petroleum, A.2, Poultry, Accuracy and precision, Application, White, Lettuce, Risk, ESCB, University of Siegen, OECD, Chapter One, Lipstick, Sack, XT, BIC, Garlic, Consumption, Sokol, Meat, VAR, Database, Section 3, Rusk, American Economic Journal, Royal, Curd, Overalls, Lamb, Great Lockdown, Fruit, Economy, COICOP, International Journal of Forecasting, Aftershave, Section 2, Nonparametric statistics, Attention, Conference, CPI, Heat, Public economics, Common sunflower, Nowcasting, American Economic Review, Computational Statistics (journal), GFK, COVID-19 pandemic, Exercise, Shock, Running, UNECE, Edible, Gambling, Banco, Rigid transformation, European Commission, Frozen, C.2, PRISMA, Official statistics, Concept, Drink, Transaction data, Somatosensory system, Punctuality, Altbier, Food prices, Response, GDP, Index, E31, Cabinet of Germany, Holiday, Machine learning, Series, Green, Whisky, Vegetable, Cola, Journal of Econometrics, Sadik Harchaoui, University, Aggregate, World Bank Group, B.1, Use, Book, Economic statistics, Civil service commission, 1L, Apple, Bread, Filter, Central bank, Brandeis University, Economic Modelling, Bank, Barkan, Roulade, Dairy product, Neural network, Reproduction, IMF, Section, ID, Data, D4L, Cryptocurrency
Key Points: 

    Draft revised Heads of Medicines Agency / European Medicines Agency guidance document on the identification of personal data and commercially confidential information within the structure of the marketing authorisation application dossier

    Retrieved on: 
    Thursday, April 18, 2024
    Steps, Union, Patient, CTD, Syndrome, CCI, Local, Disclosure, Toxicity, Process validation, MAH, Clinical trial, IP, RMP, Pharmacovigilance, Cell, Legislation, Annex, Trial of the century, Escherichia coli, Safety, Pediatrics, INTRODUCTION, Documentation, Prevalence, Vital signs, Tablet, Design, Transparency, Conclusion, Pip, Analysis, European Parliament, INN, Record, Quality, Generic, Biology, CMO, Genotoxicity, Composition, CTIS, Uncontrolled, Health care, European Medicines Agency, Prejudice, Committee, Policy, HCP, Animal, Characterization, Cell bank, Fertility, IRB, CMOS, Risk management, Private law, European Pharmacopoeia, Telephone, Research, Good, Data Protection Directive, Ampere-hour, IEC, QP, Human, Personal data, Labelling, Bibliography, Figure, MAA, R4, Institutional review board, Elucidation, Marketing, M4, ChromeOS, Contract research organization, Mental, Impairment, Toxicokinetics, NCA, Independent, Metabolite, Drug, Risk, Metabolism, GMO, Organ, EMA, Common Technical Document, General Data Protection Regulation, Confidentiality, PPD, PI, Language, DRUG, Privacy, Result, Claimed, Medication, Comparison, Ethics, Drive, PD, Narrative, EEA, Developmental toxicity, Saccharomyces cerevisiae, Pharmacopoeia, PIP, MCB, HMA, Physical chemistry, Midol, Particle size, Council, GCP, European Economic Area, Draft, Fermentation, Overview, Justification, Control, Dicarboxylic acid, Pharmacology, WCB, Expert, Immunogenicity, Data, Study, Publication, European, ICH, Element, Analytical procedures (finance auditing), Name, Common, Guideline, Exceptional circumstances, ID, Liver, Chin Na, Toxicology, Protein primary structure, Immunosuppressive drug, Vaccine

    See websites for contact details

    Key Points: 
      • See websites for contact details
        Heads of Medicines Agencies www.hma.eu
        European Medicines Agency www.ema.europa.eu

        11

        Table of contents

        12

        Abbreviations .............................................................................................. 3

        13

        Definitions ................................................................................................... 4

        14

        1.

      • redaction, masking,

        68

        hiding) in such a manner that the recipient can no longer attribute the resulting information to a data

        69

        subject and make it identifiable.

      • 81

        Contract Manufacturing Organisation (CMO): shall mean an arrangement under which a

        82

        manufacturer provides upstream manufacturing services under contract on behalf of third-party

        83

        pharmaceutical companies.

      • 94

        Protected Personal Data (PPD): shall mean any personal data which should be protected from

        95

        disclosure.

      • ?Finalised? shall mean that the marketing

        102

        authorisation (MA) has been granted or refused or that the MAA has been withdrawn.

      • The application of the general principles laid down in this guidance is without prejudice to

        106

        national rules on transparency.

      • The guidance should be read in conjunction with the relevant applicable

        107

        legislation and case law on transparency and data protection.

      • 117

        This guidance document is intended to apply to information/documents on medicinal products for

        118

        human use, for which the procedure has been finalised under the national, mutual recognition,

        119

        decentralised and centralised procedures.

      • Third

        124

        parties shall be informed or consulted as needed depending on respective national and European legal

        125

        frameworks.

      • 140

        In the following sections, the agreed principles on PD and CCI are presented, including guidance on

        141

        whether such information can be disclosed.

      • EMA/131365/2024

        Page 5/50

        142

        Any information identified as PD or CCI must be subject to a preliminary review by the EMA/NCA prior

        143

        to the possible disclosure of the information/documents.

      • Principles on the protection of personal data (PD)

        145

        The protection of PD is enshrined in EU legislation; it is a fundamental right of EU citizens.

      • In

        146

        compliance with the applicable European/national legislation, PD should be anonymised in order to

        147

        avoid the disclosure of the document undermining the privacy and integrity of any individual.

      • EMA/NCA applies a risk-based approach to assess which PD elements are to be

        152

        removed from the information/documents in order to limit the risk of re-identification.

      • are included in the MAA dossier because they have a legally

        164

        defined role or responsibility and it is in the public interest to disclose this data.

      • 168

        Applicants are advised that non-essential information (e.g., personal address, personal phone number)

        169

        should not be included in the MAA dossier.

      • The

        183

        confidentiality of records that could identify subjects should be protected, respecting the privacy and

        184

        confidentiality rules in accordance with the applicable regulatory requirement(s).

      • 185

        The applicant remains responsible for compliance with the relevant legislation in cases where such data

        186

        is inadvertently included in the MAA dossier.

      • 188

        EMA/NCA applies a risk-based approach to assess which personal data elements need to be removed

        189

        from the information/documents in order to limit the risk of re-identification.

      • 194

        EMA/NCA applies a risk-based approach to assess which personal data elements need to be removed

        195

        from the information/documents in order to limit the risk of re-identification.

      • 205

        Any proposal to consider information as commercially confidential should be properly justified by the

        206

        owner of the information.

      • In this respect, any reference(s) to the risk of that interest being

        209

        undermined should be foreseeable and not purely hypothetical.

      • 210

        Information that is already in the public domain is not considered to be commercially confidential.

      • Information on the Quality and Manufacturing of medicines

        226

        A general principle regarding quality and manufacturing information is that detailed information could

        227

        be considered commercially confidential but general information should be disclosed.

      • 234

        In general, and if not in the public domain, the names of manufacturers or suppliers of the active

        235

        substance or the excipients are considered commercially confidential.

      • 248

        A general description of the type of test methods used and the appropriateness of the specification is

        249

        not commercially confidential.

      • General information on the fermentation and purification process

        259

        is not commercially confidential, although details including operating parameters and specific material

        260

        requirements are commercially confidential.

      • 273

        A general description of the type of test methods used and the appropriateness of the specification is

        274

        not commercially confidential.

      • In general, the data included in clinical trial study reports is considered to be data that can be

        283

        disclosed once PD has been anonymised.

      • 338

        In each module, a non-exhaustive list of information that may be considered protected personal data (PPD) or commercially confidential information

        332
        333

        339

        (CCI) is included.

      • ?

        Direct contact details such as telephone

        Therefore, please refer to the appropriate sub-

        number, fax number, email, postal address,

        modules hereafter for guidance.

      • ?

        Information that may reveal strategic
        (contractual) agreements

        ?

        Any quality information on the clinical batches

        principal investigator

        that might be included here (such as e.g.

      • ?

        Information that may reveal strategic
        (contractual) agreements

        principal investigator

        Study Reports
        5.3.3.3

        as the evaluation of new formulation, innovative

        number, fax number, email, postal

        Paediatric Development Plan (PIP), etc.

      • This may include taking into

        More Than One Study
        5.3.5.4

        Other Clinical Study Reports

        5.3.6

        Reports of Post-Marketing
        Experience

        5.3.7

        Direct identifiers such as name,
        signature, contact details, etc.

    EQS-News: ID Finance Achieves Carbon Footprint Verification for 2022 and Sets Sights on 2023 Verification

    Retrieved on: 
    Wednesday, April 10, 2024
    Electricity, Certification, Climate change, Holdridge life zones, GHG, Bureau Veritas, Carbon, ID Finance, CO2, ID, ISO, Renewable energy

    19th of March 2024 – ID Finance, a leading Fintech company in Spain and Mexico, has successfully obtained from certified by Bureau Veritas the carbon footprint verification for the year 2022.

    Key Points: 
    • 19th of March 2024 – ID Finance, a leading Fintech company in Spain and Mexico, has successfully obtained from certified by Bureau Veritas the carbon footprint verification for the year 2022.
    • In 2022, ID Finance conducted a comprehensive greenhouse gas (GHG) inventory, meticulously adhering to the ISO 14064-1:2019 standards.
    • Looking ahead, ID Finance is in the process of verifying its carbon footprint for 2023.
    • Furthermore, ID Finance was honored by UK magazine Capital Finance International as the 2023 global award winner for Best ESG Inclusive Finance Solutions, affirming its leadership in responsible and sustainable business practices.

    EQS-News: NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS

    Retrieved on: 
    Wednesday, April 10, 2024
    Appendix, Letter, Exercise, EEST, The Annual Report, Audit committee, Annual, Audit, Annual general meeting, Remuneration, Report, Register, Person, PwC, Proxy, Book, Annual report, Chapter Five, Auditor, EUR, Chapter Ten, Frankfurt Stock Exchange, Notice, Address, KHT, Mass meeting, Treasury, ID, Malta Business Registry, Security (finance)

    The Board of Directors proposes to the Annual General Meeting that, for the financial year 2023, a dividend of EUR 0.19 per share be distributed.

    Key Points: 
    • The Board of Directors proposes to the Annual General Meeting that, for the financial year 2023, a dividend of EUR 0.19 per share be distributed.
    • Shareholders, who are registered in the shareholders’ register of the Company, and who wish to participate in the General Meeting, must register for the meeting by giving prior notice of participation as instructed below.
    • Shareholders may participate in the General Meeting of Shareholders and exercise their rights at the meeting by way of proxy representation.
    • On the date of this notice to the Annual General Meeting of Shareholders, dated 28 March 2024, the total number of shares in Multitude SE is 21,723,960 and each of these shares carries one vote.

    Banco Itaú Chile Schedules First Quarter 2024 Financial Results, Conference Call and Webcast

    Retrieved on: 
    Wednesday, April 10, 2024
    ID

    SANTIAGO, Chile, April 09, 2024 (GLOBE NEWSWIRE) -- BANCO ITAÚ CHILE (SSE: ITAUCL) announced today that it will release its results for the first quarter ended March 31, 2024, before the market opens in Santiago on Tuesday, April 30, 2024.

    Key Points: 
    • SANTIAGO, Chile, April 09, 2024 (GLOBE NEWSWIRE) -- BANCO ITAÚ CHILE (SSE: ITAUCL) announced today that it will release its results for the first quarter ended March 31, 2024, before the market opens in Santiago on Tuesday, April 30, 2024.
    • On Thursday, May 2, 2024, at 11:00 A.M. Santiago time (11:00 A.M.
    • ET), the Company’s management team will host a conference call to discuss the financial results.
    • The call will be hosted by Gabriel Moura, Itaú Chile’s Chief Executive Officer; Rodrigo Couto, Itaú Chile’s Chief Financial Officer, and Claudia Labbé Montevecchi, Head of IR and Chief Sustainability Officer.

    Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

    Retrieved on: 
    Tuesday, April 9, 2024
    Well, BRM, Acetyltransferase, Gene expression, Survival, NSCLC, PD, SMARCA2, Neoplasm, Megakaryocyte, Cancer, Prostate, Lung cancer, Protein, IND, EP300, AACR, ATPase, Therapy, BRG1, Safety, CBP, Lilly, Anemia, ID, Thrombocytopenia, Annual general meeting, Pharmaceutical industry

    CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.

    Key Points: 
    • “Notably, our first-in-class BRM selective inhibitor FHD-909 has demonstrated favorable tolerability and encouraging dose-dependent single agent activity in preclinical models of BRG1 mutated tumors.
    • Additionally, we are applying our long-acting formulation capabilities to our degrader programs, which further enhances the clinical potential of these drug candidates.
    • However, the ATPase domains of BRM and BRG1are 92% identical which has made identifying a selective BRM inhibitor challenging.
    • Attempts to selectively inhibit CBP or EP300 individually have been challenging due to the high homology between the two proteins.

    Identity & Access Forum Spring Market Snapshot: Mobile Driver’s Licenses, Biometrics and Access Management Innovation

    Retrieved on: 
    Tuesday, April 9, 2024
    Mastercard, Facial recognition, Counterfeit, Organization, Government, Ecosystem, Growth, Apple, DHS, Education, Patient, Travel, Research, Forum, DSCSA, Identity, NIST, Woman, Statistics, Generation Z, Fraud, String interpolation, RIV, Interest, Access, ID, IDS, Arizona Department, TSA, Gen, Android, Map, Online shopping

    The future of identity and authentication is digital and mobile driver’s licenses are the next step in identity credentialing.

    Key Points: 
    • The future of identity and authentication is digital and mobile driver’s licenses are the next step in identity credentialing.
    • Eric Jorgensen, director of the Arizona Department of Transportation’s Motor Vehicle Division, shared this sentiment while delivering the Identity and Access Forum Meeting’s keynote address.
    • The Identity and Access Forum’s primary focus is to provide a platform for solving cross-industry challenges and promoting innovation.
    • By joining the Secure Technology Alliance, members will have access to activities within the U.S. Payments Forum and the Identity and Access Forum and additional Alliance working committees.

    Florida's Premier Medical Marijuana Provider FLUENT™ Expands with New Dispensary in Daytona Beach

    Retrieved on: 
    Friday, April 5, 2024
    ID, Patient, Travel, Daytona, Environment, Hospital

    Patients with a valid medical marijuana card and ID can now explore FLUENT's sought-after selection of premium cannabis products, including flower, concentrates, edibles, tinctures and more.

    Key Points: 
    • Patients with a valid medical marijuana card and ID can now explore FLUENT's sought-after selection of premium cannabis products, including flower, concentrates, edibles, tinctures and more.
    • “Our new storefront in the vibrant city of Daytona Beach exemplifies our dedication to creating a seamless and convenient patient experience,” said Robert Beasley, CEO of FLUENT.
    • “Up until now, coastal residents would have to travel up north to Jacksonville or south to Cocoa to reach a FLUENT dispensary.
    • Florida residents interested in obtaining a medical marijuana card can visit GetFLUENT.com/GetYourCard to learn more.

    Triumph Financial Announces Schedule for First Quarter 2024 Earnings Release and Conference Call

    Retrieved on: 
    Friday, April 5, 2024
    File, International, ID, News, CFO, Cryptocurrency

    DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) today announced that it expects to release its first quarter financial results and management commentary after the market closes on Wednesday, April 17, 2024.

    Key Points: 
    • DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) today announced that it expects to release its first quarter financial results and management commentary after the market closes on Wednesday, April 17, 2024.
    • Upon filing, the financial results and commentary will be available on the Company’s website at tfin.com .
    • Aaron P. Graft, Vice Chairman and CEO, and Brad Voss, CFO, will review the financial results in a conference call with investors and analysts beginning at 9:30 a.m. central time on Thursday, April 18, 2024.
    • An archive of this conference call will subsequently be available at this same location, referenced above, on the Company’s website.

    California Water Service Group Schedules 2024 First Quarter Earnings Results Announcement and Conference Call

    Retrieved on: 
    Thursday, April 4, 2024
    ID, Senior, SAN, California Water Service Group

    SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- California Water Service Group (NYSE: CWT) today announced that its 2024 first quarter earnings results will be released at 9:00 a.m.

    Key Points: 
    • SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- California Water Service Group (NYSE: CWT) today announced that its 2024 first quarter earnings results will be released at 9:00 a.m.
    • ET with its earnings conference call to follow at 11:00 a.m.
    • ET on Thursday, April 25, 2024.
    • ET on Thursday, April 25, 2024 through June 24, 2024, at 1-800-770-2030 or 1-609-800-9909 and key in ID# 8751121, or by accessing the webcast above.